![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: PLA2G7 |
Gene summary for PLA2G7 |
![]() |
Gene information | Species | Human | Gene symbol | PLA2G7 | Gene ID | 7941 |
Gene name | phospholipase A2 group VII | |
Gene Alias | LDL-PLA2 | |
Cytomap | 6p12.3 | |
Gene Type | protein-coding | GO ID | GO:0002376 | UniProtAcc | Q13093 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
7941 | PLA2G7 | HCC2 | Human | Liver | HCC | 5.82e-05 | 6.14e-01 | 0.5341 |
7941 | PLA2G7 | HCC5 | Human | Liver | HCC | 2.57e-02 | 3.37e-01 | 0.4932 |
7941 | PLA2G7 | Pt13.a | Human | Liver | HCC | 1.41e-07 | 3.20e-01 | 0.021 |
7941 | PLA2G7 | Pt13.c | Human | Liver | HCC | 2.85e-03 | 2.54e-01 | 0.0076 |
7941 | PLA2G7 | Pt14.d | Human | Liver | HCC | 3.05e-02 | 1.54e-01 | 0.0143 |
7941 | PLA2G7 | S014 | Human | Liver | HCC | 2.66e-13 | 5.20e-01 | 0.2254 |
7941 | PLA2G7 | S015 | Human | Liver | HCC | 4.55e-16 | 8.53e-01 | 0.2375 |
7941 | PLA2G7 | S016 | Human | Liver | HCC | 1.18e-15 | 8.02e-01 | 0.2243 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Liver | ![]() | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:004424222 | Liver | HCC | cellular lipid catabolic process | 134/7958 | 214/18723 | 2.07e-09 | 5.79e-08 | 134 |
GO:00066444 | Liver | HCC | phospholipid metabolic process | 214/7958 | 383/18723 | 7.25e-08 | 1.48e-06 | 214 |
GO:003444021 | Liver | HCC | lipid oxidation | 73/7958 | 108/18723 | 1.17e-07 | 2.25e-06 | 73 |
GO:004648611 | Liver | HCC | glycerolipid metabolic process | 215/7958 | 392/18723 | 4.54e-07 | 7.49e-06 | 215 |
GO:003025821 | Liver | HCC | lipid modification | 123/7958 | 212/18723 | 3.50e-06 | 4.58e-05 | 123 |
GO:001604221 | Liver | HCC | lipid catabolic process | 175/7958 | 320/18723 | 6.50e-06 | 7.88e-05 | 175 |
GO:00066504 | Liver | HCC | glycerophospholipid metabolic process | 168/7958 | 306/18723 | 7.27e-06 | 8.62e-05 | 168 |
GO:00464342 | Liver | HCC | organophosphate catabolic process | 89/7958 | 155/18723 | 1.24e-04 | 1.03e-03 | 89 |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
PLA2G7 | SNV | Missense_Mutation | c.1195N>G | p.His399Asp | p.H399D | Q13093 | protein_coding | tolerated(0.38) | benign(0) | TCGA-DD-A115-01 | Liver | liver hepatocellular carcinoma | Male | <65 | III/IV | Chemotherapy | unknown | SD | |
PLA2G7 | SNV | Missense_Mutation | c.1195N>G | p.His399Asp | p.H399D | Q13093 | protein_coding | tolerated(0.38) | benign(0) | TCGA-DD-A1EE-01 | Liver | liver hepatocellular carcinoma | Male | >=65 | III/IV | Unknown | Unknown | PD | |
PLA2G7 | SNV | Missense_Mutation | c.509N>G | p.His170Arg | p.H170R | Q13093 | protein_coding | tolerated(0.69) | benign(0.019) | TCGA-50-6590-01 | Lung | lung adenocarcinoma | Female | >=65 | I/II | Chemotherapy | paclitaxel | CR | |
PLA2G7 | SNV | Missense_Mutation | c.170N>T | p.Pro57Leu | p.P57L | Q13093 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-91-6831-01 | Lung | lung adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
PLA2G7 | SNV | Missense_Mutation | c.22G>T | p.Val8Leu | p.V8L | Q13093 | protein_coding | tolerated_low_confidence(0.34) | benign(0.006) | TCGA-L9-A8F4-01 | Lung | lung adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
PLA2G7 | SNV | Missense_Mutation | novel | c.888T>A | p.Asp296Glu | p.D296E | Q13093 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-56-7730-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Chemotherapy | unknown | PD |
PLA2G7 | SNV | Missense_Mutation | novel | c.1234N>C | p.Asp412His | p.D412H | Q13093 | protein_coding | tolerated(0.12) | possibly_damaging(0.586) | TCGA-56-7822-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Chemotherapy | eloxatin | PD |
PLA2G7 | SNV | Missense_Mutation | c.677N>A | p.Ala226Glu | p.A226E | Q13093 | protein_coding | deleterious(0) | probably_damaging(0.981) | TCGA-60-2698-01 | Lung | lung squamous cell carcinoma | Male | <65 | I/II | Chemotherapy | mithramycin | PD | |
PLA2G7 | SNV | Missense_Mutation | novel | c.518N>C | p.Ile173Thr | p.I173T | Q13093 | protein_coding | deleterious(0) | probably_damaging(0.983) | TCGA-CN-A497-01 | Oral cavity | head & neck squamous cell carcinoma | Male | <65 | III/IV | Unknown | Unknown | SD |
PLA2G7 | SNV | Missense_Mutation | novel | c.712N>C | p.Asp238His | p.D238H | Q13093 | protein_coding | deleterious(0) | probably_damaging(0.924) | TCGA-CV-5442-01 | Oral cavity | head & neck squamous cell carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 5 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
7941 | PLA2G7 | DRUGGABLE GENOME, ENZYME | inhibitor | 178103948 | RILAPLADIB | |
7941 | PLA2G7 | DRUGGABLE GENOME, ENZYME | inhibitor | CHEMBL2104981 | RILAPLADIB | |
7941 | PLA2G7 | DRUGGABLE GENOME, ENZYME | Rilapladib | RILAPLADIB | ||
7941 | PLA2G7 | DRUGGABLE GENOME, ENZYME | DARAPLADIB | DARAPLADIB | ||
7941 | PLA2G7 | DRUGGABLE GENOME, ENZYME | inhibitor | 354702268 | ||
7941 | PLA2G7 | DRUGGABLE GENOME, ENZYME | Indolizine derivative 1 | |||
7941 | PLA2G7 | DRUGGABLE GENOME, ENZYME | inhibitor | 354702269 | ||
7941 | PLA2G7 | DRUGGABLE GENOME, ENZYME | inhibitor | 375973250 | ||
7941 | PLA2G7 | DRUGGABLE GENOME, ENZYME | ERYTHROPOIETIN | EPOETIN BETA | 16421163 | |
7941 | PLA2G7 | DRUGGABLE GENOME, ENZYME | GSK2647544 |
Page: 1 2 |